Table 1.
Main characteristics of the studies relating MCP-1 to Patients’ Prognosis
| First author (years) | Country | Mean age (years) | N (Male %) | Technology | Distant metastasis (%) | MCP-1 + (%) | Tumor location | Analysis | Cut-off for MCP-1 + | TNM (+/-) |
|---|---|---|---|---|---|---|---|---|---|---|
| Qian et al (2012) | China | 65.5 | 48 (60.76) | ELISA | 28.57 | 55.7 | Lung | OS, STAGE | >3301 pg/mL | 79 (55/24) |
| Zhang et al (2012) | China | 60.4 | 79 (58.96) | HIER | 3.73 | 79.85 | Lung | OS, STAGE | >10% | 134 (107/27) |
| Suguru et al (2011) | Japan | 66 | 110 (100) | ELISA | NR | 19.09 | Prostate | DFS | score 3 to 7 | NR |
| Lu et al (2010) | China | 46 | 227 (76) | ELISA | 24 | 54 | Nasopharynx | OS, DFS, STAGE | >311 pg/ml | 297 (205/92) |
| Yoshidome et al (2009) | Japan | 60.3 | 55 (63.22) | MART | 43.68 | 56.32 | Liver | OS | >10% | NR |
| JOHN et al (2008) | Norway | 62.2 | NR | ELISA | NR | 78.31 | Head and neck | OS, STAGE, DFS | >7207pg/ml | 65 (34/31) |
| Hideki et al (2008) | Japan | 65.2 | 66 (65.35) | ELISA | 41.58 | 50 | Ccolorectal | OS, STAGE | Ca/N Ratio >1.8 | 101 (41/60) |
| Annechien et al (2007) | Netherlands | 59 | 0 (0) | CBA | NR | 50 | Ovarian cancer | OS, PFS, STAGE | >253.28 pg/mL | 186 (119/67) |
| Naohiko et al (2004) | Japan | NR | 42 (75) | ABC | 28.57 | 55.36 | Esophagus | OS | >10% | NR |
| Paolo et al (2003) | Italy | 66 | 35 (56.14) | ELISA | 30.4 | 61.29 | Pancreatic | OS | >91 pg/ml | NR |
| Takayuki et al (2000) | Japan | 55 | NR | ELISA | 39.7 | 48.15 | Breast | OS | >10% | NR |
Abbreviations: NR, not reported; IHC, immunohistochemistry; MART, Microwave Antigen Retrieval Technique; CBA, Cytokine Bead Array; ABC, Avidin-Biotin Complex method; MCP-1 Ca/N ratio, the cancer tissue MCP-1 concentration divided by normal mucosa MCP-1 concentration.